{"id":"W2403219295","doi":"10.1158/1538-7445.sabcs15-s6-01","title":"Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Clinical endpoint; Internal medicine; Oncology; Population; Breast cancer; Cancer; Metastatic breast cancer; Everolimus; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026068,0.0009643464,0.001392633,0.000232921,0.0002626204,0.0008853421,0.0005859103,0.0009057493,0.01470464],"category_scores_gemma":[0.000975212,0.0004432085,0.001366965,0.0003219444,0.0005554974,0.0005790992,0.0003315921,0.001810819,0.00176844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004979527,"about_ca_system_score_gemma":0.0007119278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004934307,"about_ca_topic_score_gemma":0.001311211,"domain_scores_codex":[0.9996639,0.0001463033,0.00003029043,0.00007124176,0.00003796902,0.00005020962],"domain_scores_gemma":[0.9992788,0.000137574,0.0002305419,0.00004930567,0.0000543712,0.0002495091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464108,0.002996708,0.01276831,0.0006272848,0.001478837,0.00004214895,0.00003501436,0.000352787,0.01017423,0.00007748431,0.003093545,0.02194275],"study_design_scores_gemma":[0.7564546,0.1537262,0.07489621,0.000131617,0.004445885,0.0002896609,0.00004514197,0.001466248,0.004702329,0.0003945705,0.003391262,0.00005625123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842607,0.002419132,0.0003452097,0.0009076348,0.0001615851,0.001973107,0.006726553,0.00009804597,0.00310808],"genre_scores_gemma":[0.9879103,0.0007945378,0.0007611093,0.000639607,0.0002463944,0.001278273,0.005283013,0.00001887147,0.003067951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01470464,"threshold_uncertainty_score":0.04919195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02083531772490217,"score_gpt":0.321575235329682,"score_spread":0.3007399176047799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}